## Chugai and Taisho Terminate the Co-Marketing Agreement of Edirol<sup>®</sup>, a Treatment for Osteoporosis

TOKYO, January 22, 2021 -- <u>Chugai Pharmaceutical Co., Ltd.</u> (TOKYO: 4519) and <u>Taisho Pharmaceutical Co.,</u> <u>Ltd.</u> announced termination of the agreement between both companies regarding co-marketing of Edirol<sup>®</sup> Capsules 0.5 µg and 0.75 µg (hereafter, "Edirol"), a treatment for osteoporosis for which Chugai has a marketing authorization.

In May 2008, both companies entered into an agreement for co-development and marketing of Edirol. They have co-marketed Edirol and engaged in providing information in Japan since the launch of the product in April 2011. However, they have decided to terminate the agreement regarding co-marketing, following discussions on future marketing policies.

As such, Taisho will stop marketing and providing information on Edirol on April 10, 2021, while Chugai will solely be responsible for these activities from April 11, 2021.

Chugai and Taisho will corporate to accomplish a smooth transition. During the transition period, both companies will maintain the same level of product supply and adequate commercial activities to satisfy any medical needs.

Contact Information	
Corporate Communications Dept.,	Corporate Communications Dept.,
Chugai Pharmaceutical Co., Ltd.	Taisho Pharmaceutical Co., Ltd.
Contact from the press	Contact from the press
Media Relations Group	Media PR Group
TEL: +81-3-3273-0881	TEL: +81-3-3985-1115
Mail:pr@chugai-pharm.co.jp	Mail:pr@taisho.co.jp
Contact from analysts/investors	Contact from analysts/investors
Investor Relations Group	IR Group
TEL: +81-3-3273-0554	TEL: +81-3-3985-1115
Mail:ir@chugai-pharm.co.jp	Mail: <u>ir@taisho.co.jp</u>

Edirol<sup>®</sup> is a trademark of Chugai.